GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bloomios Inc (OTCPK:BLMS) » Definitions » EPS (Diluted)

Bloomios (Bloomios) EPS (Diluted) : $-1.26 (TTM As of Sep. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Bloomios EPS (Diluted)?

Bloomios's Earnings per Share (Diluted) for the three months ended in Sep. 2023 was $-0.42. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.26.

Bloomios's EPS (Basic) for the three months ended in Sep. 2023 was $-0.42. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-1.26.

Bloomios's EPS without NRI for the three months ended in Sep. 2023 was $-0.02. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.82.

During the past 3 years, the average EPS without NRIGrowth Rate was -516.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 10 years, Bloomios's highest 3-Year average EPS without NRI Growth Rate was 90.40% per year. The lowest was -516.90% per year. And the median was -227.10% per year.


Bloomios EPS (Diluted) Historical Data

The historical data trend for Bloomios's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomios EPS (Diluted) Chart

Bloomios Annual Data
Trend Jun02 Jun03 Jun04 Jan05 Jan06 Jan07 Jan19 Jan20 Dec21 Dec22
EPS (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.21 - - -0.16 -1.04

Bloomios Quarterly Data
Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.16 -0.64 -0.11 -0.09 -0.42

Competitive Comparison of Bloomios's EPS (Diluted)

For the Drug Manufacturers - Specialty & Generic subindustry, Bloomios's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bloomios's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bloomios's PE Ratio distribution charts can be found below:

* The bar in red indicates where Bloomios's PE Ratio falls into.



Bloomios EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

Bloomios's Diluted EPS for the fiscal year that ended in Dec. 2022 is calculated as

Diluted EPS (A: Dec. 2022 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-13.774-0)/13.200
=-1.04

Bloomios's Diluted EPS for the quarter that ended in Sep. 2023 is calculated as

Diluted EPS (Q: Sep. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-26.033-0)/61.473
=-0.42

EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bloomios  (OTCPK:BLMS) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Bloomios EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of Bloomios's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


Bloomios (Bloomios) Business Description

Traded in Other Exchanges
N/A
Address
701 Anacapa Street, Suite C, Santa Barbara, CA, USA, 93101
Bloomios Inc manufactures, markets, and distributes U.S. hemp-derived supplements and cosmetic products through wholesale distribution channels in the United States of America. It offers its private-label and white-label customers large collections of customizable hemp products that include over 80 products across 7 categories in addition to custom formulation and manufacturing services. Its product categories include edibles, tinctures, oils, salves, capsules, balms, lotions, creams, beverages, and pet treats.
Executives
Douglas S Rohrer officer: Chief Business Officer 701 ANACAPA, SUITE C, SANTA BARBARA CA 93101
Emc2 Capital Llc 10 percent owner 201 W MONTECITO STREET, SANTA BARBARA CA 93101
Barrett Evans director, 10 percent owner, officer: Pres, Chief Strategy Officer
Aline Hayuta Elkayam 10 percent owner 104 CHELSEA PLACE, ORMOND BEACH FL 32174
Bibi Daprile 10 percent owner 12 WINDING CREEK WAY, ORMOND BEACH FL 32174
Agpl Acquisition, Inc 10 percent owner 201 W MONTECITO ST., SANTA BARBARA CA 93101
Mammoth Crest Capital Llc 10 percent owner 1712 PIONEER AVE, SUITE 558, CHEYENNE WY 82001
Michael Hill director, 10 percent owner, officer: Chief Executive Officer 201 WEST MONTECITO STREET, SANTA BARBARA CA 93101
Bryan Glass director, 10 percent owner, officer: President and Director 20 WEST PARK AVENUE, SUITE 207, LONG BEACH NY 11561
Douglas Boyd director, officer: Chairman of the Board 8101 TIARA COVE CIR, LAS VEGAS NV 89128
Peter A Hogendoorn director, officer: President & CEO 13288 AMBLE GREEN PLACE, SURREY A1 V4A 6P5
Harold C Moll director, 10 percent owner
Van Laare Derek R officer: Secretary 6119 GORDON AVENUE, BURNABY A1 V5E 3M2
Carlo Civelli other: former director/officer/owner 111 SOMERSET ROAD, TRIPLE ONE SOMERSET 06-06, SINGAPORE U0 238164
Logan Anderson director, officer: President & Treasurer 15 HILL CRESCENT, PEMBROKE BERMUDA D8 00000

Bloomios (Bloomios) Headlines